GlobalData

Indian pharma companies are more likely to engage in contract/excess capacity API manufacture than companies in the other small…

The number of trials that have been impacted by slow enrollment has increased by 13.9 per cent

There are 13 Indian organisations working on COVID-19 vaccine development

Big pharma companies are searching for innovative biotechs to invest in the rare diseases space

Both drugs have seen a sharp decline in price since the availability of the first generic in India

New data suggest that some hard-hit communities may be better protected for COVID-19 resurgence, while other communities are not

By the end of March 2020, Semglee was approved in 60 countries and launched in several countries including the EU, Australia and…

High-risk groups include older patients, those with pre-existing conditions, at-risk ethnicities and healthcare workers

Clinical trials in India also growing at a higher rate, and the country is now in fourth place for COVID-19 trials

COVID-19 may also be disrupting other therapy areas by reducing service agreements for other non-COVID-19 drugs